Search clinical trials for: BRCA

Total 508 results

University Health Network, Toronto
Women's College Hospital; Canadian Breast Cancer Foundation; Vancouver General... and other collaborators

Completed

One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure (AllodermRCT)

Breast Cancer

Canada
Grupo Español de Linfomas y Transplante Autólogo...
Janssen-Cilag, S.A.

Completed

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Diffuse, Large B-Cell, Lymphoma

Spain
Jules Bordet Institute

Active, not recruiting

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

Breast Cancer

United States, Belgium, Israel, France, Italy, Spain, Brazil, Mexico, Poland, Portugal, Switzerland
Sheba Medical Center

Unknown

Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers

Hereditary Breast and Ovarian Cancer Syndrome

Israel
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
Sidney Kimmel Comprehensive Cancer Center at Johns...
Van Andel Research Institute

Withdrawn

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions

United States
Azienda Ospedaliera Universitaria Policlinico Paolo...

Unknown

BRCA Main Home Nutritional Intervention-random Study

BRCA1 Mutation | BRCA2 Mutation

Italy
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
University Hospital, Montpellier

Completed

Management of Women With BRCA1/2 Mutation

BRCA1 Mutation | BRCA2 Mutation

France
AbbVie

Completed

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Japan
National Cancer Institute (NCI)

Completed

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditions

United States
National Human Genome Research Institute (NHGRI)
Johns Hopkins Bloomberg School of Public Health

Completed

Adaptation to Living With a BRCA1/2 Mutation

Cancer Genetics

United States
Memorial Sloan Kettering Cancer Center

Withdrawn

Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer

Melanoma | Gastric Cancer | Non-Hodgkin's Lymphoma | Lung Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Uterine Cancer | CORPUS UTERI,ENDOMETRIUM | LUNG | OVARY

United States
William K. Oh
Prostate Cancer Foundation

Completed

Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca

Prostate Cancer

United States
Women and Infants Hospital of Rhode Island

Completed

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing

Breast Cancer

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Evaluation of Tomosynthesis for Characterization and the Management of Breast Lesions (ETOLE)

Breast Neoplasms | BRCA1 Protein | BRCA2 Protein | Tomosynthesis

France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Breast Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
AbbVie

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Oncology | High Grade Serous Ovarian Cancer | BRCA Mutated | BRCA Mutated Breast Cancer
AbbVie

Completed

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Breast Cancer | Hepatocellular Carcinoma | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Melanoma | Primary Peritoneal Cancer | Non-hematologic Malignancies
AbbVie

Completed

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

Ovarian Cancer

Japan
Pearl Network

Completed

Assessing the Effects of Three Oral Care Regimens

Gingivitis | Dental Plaque

United States
Memorial Sloan Kettering Cancer Center

Completed

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer

Breast Cancer

United States
Georgetown University

Completed

Psychosocial Intervention Pilot for Partners in BRCA Testing

Breast Cancer
Rabin Medical Center

Unknown

Prostate Cancer Screening Among Men With High Risk Genetic Predisposition

Lynch Syndrome | BRCA1 Syndrome | BRCA2 Syndrome

Israel
The University of Texas Health Science Center at...

Withdrawn

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Ovarian Cancer | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation
AstraZeneca
Optum, Inc.

Completed

Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer (ENGAGE)

Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer

United States, Italy, Spain
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States
Rabin Medical Center

Unknown

The Link Between BRCA Mutation and Endothelial Function

BRCA1 Gene Mutation | BRCA2 Gene Mutation

Israel
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Breast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Eunice Kennedy Shriver National Institute of Child...

Completed

Insulin Resistance and Breast Cancer

Breast Cancer | Insulin Resistance

United States
Georgetown University
National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)

Completed

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Breast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2)

United States
National Cancer Institute (NCI)

Completed

Phase II ABT-888 With Cyclophosphamide

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Triple-Negative Breast Cancer | Serous Carcinoma Cancer

United States, Canada
Georgetown University
National Cancer Institute (NCI)

Completed

Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations

Breast Cancer
Georgetown University
National Cancer Institute (NCI)

Completed

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

Breast Cancer

United States
Fundación Pública Andaluza para la gestión de la...

Completed

Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer (BERNAQ)

Breast Cancer

Spain
AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia
Alexandru Eniu
Iuliu Hatieganu University of Medicine and Pharmacy

Completed

BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival

To Determine the Prevalence, Penetrance of BRCA1 and BRCA2 Mutations in Romanian Womens With Breast or Ovarian Cancer

Romania
Dana-Farber Cancer Institute

Completed

Cabozantinib for Metastatic Triple Negative BrCa

Breast Cancer

United States
Georgetown University

Completed

Registry of Mastectomy for Breast Cancer Risk Reduction

Quality of Life | Breast Neoplasms | Genetic Predisposition to Disease | Adjustment Disorder | Mastectomy

United States
Vejle Hospital
Abbott

Completed

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (Veli-BRCA)

Recurrent, Epithelial Ovarian Cancer

Denmark
Samsung Medical Center
AstraZeneca

Completed

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer
University of Pennsylvania
United States Department of Defense

Completed

Genetic Counseling in African American Women

Breast Cancer | Ovarian Cancer

United States
Cynvenio Biosystems

Unknown

A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.

Triple Negative Breast Cancer | BRCA Mutation | Natural Killer Cells

United States
Northwestern University

Completed

4R for Guideline Indicated BRCA Testing of Breast Center Patients (4R)

Genetic Predisposition to Disease | Newly Diagnosed Carcinoma of Breast

United States
Women's College Hospital
Canadian Institutes of Health Research (CIHR); London Health Sciences Centre; H. Lee Moffitt Cancer Center and Research Institute and other collaborators

Unknown

Cancer Prevention in Women With a BRCA Mutation

Breast Cancer | Ovarian Cancer | BRCA1 Gene Mutation | BRCA2 Gene Mutation

Canada
Cancer Research UK

Completed

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Breast Cancer | Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United Kingdom
AstraZeneca
Myriad Genetic Laboratories, Inc.

Withdrawn

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Platinum Sensitive Relapsed Ovarian Cancer

United States, Korea, Republic of, Peru, United Kingdom, Philippines

Search clinical trials for: BRCA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations